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ABSTRACT
Respiratory infection is very common in patients suffering from cystic fi brosis (CF). However, the 
antimicrobial resistance rate of isolates from CF patients is not often documented. In this study, 
279 respiratory specimens of 146 patients were prospectively collected from July to December 2006. 
Microbiological cultures and antimicrobial susceptibility tests of the most frequently isolated bac-
teria were performed. Sputum and oropharyngeal swabs were processed for culture. During the 
study period, 50% of the patients harbored Staphylococcus aureus, 35% Pseudomonas aeruginosa, 
4.7% Haemophilus infl uenzae. Methicillin resistant S. aureus (MRSA) were detected in 8 (6%) pa-
tients; ESBL and MBL-producing P. aeruginosa were not identifi ed in these patients. The detection 
of MRSA in CF patients confi rms that antimicrobial resistance patterns should be always kept under 
surveillance. Moreover, hygiene regulations in CF clinics should prevent a further spread of resistant 
bacterial strains.
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BACKGROUND
The main feature of cystic fibrosis (CF) is 
chronic respiratory infection, which may 
start very early in the life of these patients. 
Since the early description of CF, pulmo-
nary infection has been recognized as playing 
the greatest role in morbidity and mortality 
leading to premature death in 90% of pa-
tients.1 Impairment of the muco-ciliary 
transport and thus the cleaning function 
of the upper airway predisposes for bacte-
rial colonization and chronic infections 
by Staphylococcus aureus and Pseudomonas 
aeruginosa.1,2 Subsequently, the microbiology 
of CF becomes more complex when other 
non-fermenting Gram-negative organisms, 
such as members of the Burkholderia cepacia-
complex ensue and Pseudomonas aeruginosa 
switch to the mucoid phenotype, which is 
more difficult to eradicate.3,4
Increase in multidrug-resistance in Gram-
negative pathogens such as Pseudomonas 
aeruginosa and Burkholderia cepacia complex 
makes the therapeutic management of CF 
patients more complex since the therapeutic 
options are very limited.5 Thus, careful isola-
tion and identification, and accurate studies 
of susceptibility to antibiotics are critical for 
predicting the spread of strains, improving 
therapeutic measures and facilitating our 
understanding of the epidemiology of these 
pathogens. The aim of this study was to de-
termine the prevalence of pathogens isolated 
from respiratory samples of CF patients re-
ceiving care at the Referral Cystic Fibrosis 
Center of Bahia, and to evaluate the spec-
trum of antimicrobial-resistance of these 
organisms.
 
METHODS
Patients and samples
A clinical laboratory study including 146 pa-
tients attending regularly the Referral Center 
for Cystic Fibrosis of Bahia, Hospital Otavio 
Mangabeira, between July and December 2006 
was conducted. The diagnosis of CF was con-
firmed according to the criteria of the Cystic 
Fibrosis Foundation.6 Spontaneous and in-
duced sputum samples and oropharyngeal 
swabs were obtained for each patient during 
periods of clinical stability at regular clinical 
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and physiotherapy attendance was performed every three 
months. Patients with history of antibiotic therapy in the 
last 90 days were excluded.
Processing of sputum samples and culture of 
organisms
Spontaneous sputum samples obtained from all patients 
involved during the study period were mixed with equal 
volumes of 1% dithiothreitol (Merck, Germany) before 
incubation at 37 °C for 30 min. When it was not possi-
ble to obtain spontaneous sputum samples, an oropha-
ryngeal swab was used as a sample. All specimens were 
examined microscopically and cultured in agar blood, 
agar chocolate, MacConkey agar, Mannitol Salt Agar, and 
Burkholderia cepacea agar (BCSA) incubated for a period 
of 18 to 48 hours at 36 °C, followed by room temperature 
incubation for up to 72 hours. All isolates obtained from 
the samples were identified by the autoSCAN-4 (Dade 
Behring, Inc., West Sacramento, CA, USA). Preparation 
of suspensions, inoculations, incubation times, tempera-
tures, and interpretation of reactions were performed 
according to the manufacturer’s instructions. Additional 
biochemical tests for bacterial identification were per-
formed whenever necessary.
Antimicrobial susceptibility testing
Susceptibility testing of all bacterial strains was carried 
out through broth microdilution assay using an auto-
mated autoSCAN-4 system (Dade Behring, Inc., West 
Sacramento, CA, USA) and by disk diffusion technique 
according to the CLSI criteria.7
Statistical analysis
Epi-Info version 3.2 software (Centers for Disease Con-
trol and Prevention, US) was used for data entry and 
descriptive statistical analysis. Categorical and continu-
ous variables are presented as number and proportion, 
and median and range, respectively.
Ethical considerations
The study was approved by the Ethical Committee from 
the SESAB (Secretária de Saúde do Estado da Bahia). 
Written informed consent and verbal assent were ob-
tained from each patient or children’s parent or guardian 
and from all study participants, respectively.
 
RESULTS
During the study period, 146 patients (75 males, 71 fe-
males; mean age 14.5 years, ranging from 4 months to 
77 years) were referred to the Referral Center for Cystic 
Fibrosis of Bahia, Hospital Otavio Mangabeira. A total of 
369 biological samples (337 sputum and 32 oropharynx 
swabs) were analyzed and 279 bacterial strains were iso-
lated and identified. The most frequent pathogens were 
S. aureus (35%) and P. aeruginosa (21%), with the high-
est rate of colonization observed in patients in the age 
group of 6 - 10 years and above 17 years old, respectively 
(Table 1). 
In 35.6% of the samples analyzed, more than one mi-
croorganism were isolated, being the most frequent com-
bination S. aureus and P. aeruginosa, found in 10% (15 
of 146) of the patients, while 85% (125 of 146) of the 
patients had only one pathogen identified in all cultured 
samples. During the study period only one patient, a 13-
year old boy, was chronically infected by Burkholderia ce-
pacia complex, with positive cultures in all four samples 
collected monthly. This pathogen exhibited the mucoid 
phenotype and was highly susceptible to piperacillin, im-
ipenem, aminoglycosides, and ciprofloxacin.
Table 1. Prevalence of pathogens identified from respiratory specimens in patients with cystic fibrosis, 
classified by age group (n = 146)
Age Nº (%) of S. aureus Non-mucoid Mucoid K.  H.  Acineto- Alcali- Burkhol- S.  Others
(years) patients  P. aerugi- P. aerugi- pneumo- influen bacter genes deria maltho- gram- 
   nosa nosa niae -zae spp spp sp philia negative
≤ 1 17 (12%) 7 1 1 5 2 0 0 0 1 6
2 - 5 28 (19%) 14 3 3 2 2 0 1 0 1 12
6 - 10 41 (28%) 29 0 5 2 1 1 0 0 0 15
11 - 17 28 (19%) 11 5 2 1 0 1 0 1 0 6
≥ 17 32 (22%) 12 8 6 2 2 2 2 0 1 10
Total 146 73 34 17 12 7 4 3 1 3 49
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Susceptibility studies of P. aeruginosa over the study 
period are summarized in Table 2. In this population, non-
mucoid P. aeruginosa isolates exhibited a much higher anti-
microbial susceptibility than the mucoid strains, being fully 
susceptible to imepenem and meropenem. Both phenotypes 
were mainly gentamicin-resistant (45% and 44%), respec-
tively.
Methicillin resistant Staphylococcus aureus (MRSA) was 
isolated from 6% of the patients. Among these, MRSA iso-
lates showed no resistance against vancomycin, linezolid and 
rifampicin. Constitutive clindamycin resistance was detected 
in 10% of the isolates, and inducible clindamycin resistance 
was not identifi ed in this study population. Rates of suscep-
tibility of S. aureus are presented in Table 3. 
Table 2. Rate of susceptibility (%) of mucoid and non-
mucoid Pseudomonas aeruginosa isolates against 
different antimicrobial agents
Antimicrobial  Rate of susceptibility (%) 
agents  Non-Mucoid  Mucoid
  P. aeruginosa (42)  P. aeruginosa (17)
Amikacin 83  75
Aztreonam 83  75
Ceftazidime 79  75
Ciprofloxacin 79  88
Gentamicin 55  56
Imipenem 100  88
Meropenem 100  100
Piperacillin 88  94
Tobramycin 88  81
Table 3. Rate of susceptibility (%) of S. aureus iso-
lates against different antimicrobial agents (n = 99)
Antimicrobial agents Rate of susceptibility (%)
Amoxicillin/clavulanate 94
Cefazoline 94
Ceftriaxone 94
Ciprofloxacin 90
Clindamycin 90
Cotrimoxazole 86
Erythromycin 79
Gentamicin 96
Rifampicin 96
Linezolid 100
Vancomycin 100
DISCUSSION
Colonization by pathogenic microorganisms in the respiratory 
tract of patients with CF occurs at young age and represents a 
serious health problem because it is considered a major cause 
of morbidity and mortality.1 As reported in previous studies on 
the prevalence and antimicrobial susceptibility of bacterial iso-
lates from CF patients in USA, Germany, and South America, we 
found that Staphylococcus aureus and Pseudomonas aeruginosa 
are the most frequent pathogens in this population.8-13 The prev-
alence of S. aureus was highest (70.7%) among children of 6 to 
10 years of age. In older age group (11-17 and > 17 years of age), 
the prevalence of S. aureus isolates declined as the prevalence of 
P. aeruginosa increased. However, S. aureus remained the most 
frequently isolated bacteria, regardless of patient age group.
Methicillin resistant S. aureus (MRSA) was isolated from 
eight patients (6%) during our study, similar to the 5% re-
ported in Germany.9 The rate of MRSA in comparison with 
the total amount of S. aureus isolates was 10%. In contrast, a 
rate of methicillin resistance in CF patients as high as 18.8% 
was reported in the United States;13,14 25.9% in Argentina;11 
and 18% in Spain. Presumably, the differences in the MRSA 
rates in CF-patients correlate with the general nosocomial 
and community prevalence of MRSA of each country.
Pseudomonas aeruginosa producing metallo-β-lactamase 
(MBLs) was fi rst reported in Japan in 1991,15 and since then 
it has been described as associated with outbreaks of hos-
pital-acquired infection in several countries.16-18 The fi rst 
report of MBL-producing P. aeruginosa in CF patients was 
from Germany (5%).9 In this study sample, we did not iden-
tify any MBL or ESBL-producing P. aeruginosa isolates. Al-
though, ongoing surveillance of these multi-resistant strains 
is vital in public healthcare settings, allowing for the correct 
antimicrobial treatment of CF patients and the control of 
nosocomial infections through the implementation of suit-
able hygiene regimens.
Independently from the antimicrobial susceptibility, mu-
coid phenotypes of P. aeruginosa in CF respiratory samples 
represent a non-favorable prognostic aspect.1,19 In our study, 
mucoid P. aeruginosa isolates were observed in 12% (17 of 
146) of the patients and in all age groups, being the highest 
rate of colonization in the age group > 17 years old. The 
non-mucoid P. aeruginosa isolates exhibited a much higher 
antimicrobial susceptibility than the mucoid ones. 
However, some studies have shown that most patients 
with P. aeruginosa in the airways when clinically stable main-
tain the same strains of genotypes, when there are episodes 
of exacerbations.20
As caveat in interpreting these results cultures were taken 
only from patients clinically stable. However, some studies 
have shown that most patients with P. aeruginosa in their 
airways when clinically stable maintain the same strain gen-
otypes when episodes of exacerbations occur.20 Therefore, 
initial antibiotic therapy of an exacerbation of CF is usually 
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determined by the results of antibiotic susceptibility testing 
performed on isolates recovered from the most recent cul-
ture of that patient.1
This study was also limited by the short follow-up period 
and because the small number of some groups of patients 
infected with individual strains did not allow for correlating 
microbiological data to clinical outcomes between groups of 
patients. Our data emphasize the crucial role of microbio-
logical methods in defi ning possible therapeutic strategies 
that may help guiding antibiotic therapy regimens in CF 
patients. Further research is therefore needed to determine 
whether the bacteria repertoire in the clinical stable phase is 
the same during the exacerbation phase. 
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